Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?
International Journal of Immunotherapy and Cancer Research
Relapsed Hairy Cell Leukemia?
Abstract
Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons.
http: //www. peertechz. com/Immunotherapy-Cancer-Resea rch/pdf/IJICR-1-102.pdf
Case Report
Are Cladribine and Rituximab Enough for the Treatment ofRelapsed Hairy Cell Leukemia?
Abstract
Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons.
http:
Comments
Post a Comment